文献速递胃肠外科围术期管理与 ERAS

Ivor-Lewis食管切除术后吻合口漏与围术期因素及术中液体和升压药管理的关联:单中心回顾性队列

Association of perioperative patient characteristics, intraoperative fluid management, and vasopressors with anastomotic leakage after Ivor-Lewis esophagectomy-a single center retrospective cohort.
PubMed 文献 · Surg Endosc · 2026-02-17

该单中心回顾性队列纳入2018年1月至2024年9月接受Ivor-Lewis食管切除术的208例食管癌患者,16例(7.7%)发生吻合口漏。多变量分析显示术前P2Y12抑制剂治疗(OR 9.3,95%CI 2.4-36.3,p<0.001)和术中给予血管加压素(OR 4.0,95%CI 1.3-12.0,p=0.014)与吻合口漏独立相关。吻合口漏与住院时间延长、30天再入院和再插管增加相关,但与30天或90天死亡率无关。

要点

  • 术前P2Y12抑制剂治疗与吻合口漏独立相关(OR 9.3)。
  • 术中血管加压素使用与吻合口漏独立相关(OR 4.0)。
  • 去氧肾上腺素单药治疗组吻合口漏发生率最低(3.6%)。

核心结论

  • 术前P2Y12抑制剂治疗和术中血管加压素使用与食管切除术后吻合口漏独立相关。
  • P2Y12治疗可能反映高危血管生物学,而升压药选择是可改变因素。

研究设计与样本

  • 单中心回顾性队列研究,纳入2018年1月至2024年9月接受Ivor-Lewis食管切除术的食管癌患者208例。
  • 收集人口学、合并症、手术、升压药和液体管理数据,采用Fisher精确检验和Mann-Whitney U检验进行单因素分析,将p<0.1及临床相关协变量纳入逐步多变量logistic回归。

主要发现

  • 208例患者中16例(7.7%)发生吻合口漏。
  • 多变量分析显示术前P2Y12抑制剂治疗(OR 9.3,95%CI 2.4-36.3,p<0.001)和术中血管加压素给药(OR 4.0,95%CI 1.3-12.0,p=0.014)与吻合口漏独立相关。
  • 去氧肾上腺素单药治疗组吻合口漏发生率最低(3.6%),加用血管加压素后风险增加近五倍(18%)。
  • 吻合口漏与住院时间延长(中位18.5天 vs 9天,p<0.001)、30天再入院率升高(25% vs 3.6%,p=0.006)和再插管增加(31.3% vs 12.0%,p=0.046)相关,但与30天或90天死亡率升高无关。
  • 外周血管疾病在单因素分析中显著,但未保留在多变量模型中。

临床怎么用

  • 围术期应仔细选择升压药,去氧肾上腺素单药可能与较低吻合口漏风险相关。
  • 对术前接受P2Y12抑制剂治疗的患者应加强监测。

局限性

  • 单中心回顾性研究,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anastomotic leak (AL) is a significant complication after esophagectomy, occurring in 9-11% of cases, increasing morbidity and resource utilization. This study evaluated perioperative, surgical, and hemodynamic factors associated with AL after Ivor Lewis esophagectomy. METHODS: We conducted a retrospective study of patients who underwent Ivor Lewis esophagectomy for esophageal cancer between January 2018 and September 2024. Demographic, comorbidity, operative, vasopressor, and fluid management data were collected. Univariate analyses used Fisher's exact and Mann-Whitney U tests. Variables with p < 0.1 and clinically relevant covariates were included in stepwise multivariable logistic regression. RESULTS: Among 208 patients, 16 (7.7%) developed AL. Baseline demographics and neoadjuvant therapy did not differ between groups. In multivariable analysis, preoperative P2Y12 inhibitor therapy (OR 9.3, 95% CI 2.4-36.3, p < 0.001) and intraoperative vasopressin administration (OR 4.0, 95% CI 1.3-12.0, p = 0.014) were independently associated with AL. Phenylephrine monotherapy had the lowest AL rate (3.6%), whereas the addition of vasopressin increased risk nearly fivefold (18%). Peripheral vascular disease was significant in univariate analysis but not retained in multivariable modeling. AL was associated with a prolonged hospital stay (median 18.5 vs 9 days, p < 0.001), higher 30-day readmission (25% vs 3.6%, p = 0.006), and increased reintubation (31.3% vs 12.0%, p = 0.046), but not with higher 30- or 90-day mortality. CONCLUSIONS: Preoperative P2Y12 therapy and intraoperative vasopressin use were independently associated with AL after esophagectomy. P2Y12 therapy may reflect high-risk vascular biology, while vasopressor selection represents a modifiable factor. These findings warrant validation but support the careful selection of vasopressors and enhanced monitoring in P2Y12 patients.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Yap C, Warner R, Hoefnagel AL, et al. Association of perioperative patient characteristics, intraoperative fluid management, and vasopressors with anastomotic leakage after Ivor-Lewis esophagectomy-a single center retrospective cohort. Surg Endosc. 2026. PMID: 41703041. doi:10.1007/s00464-026-12619-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。